REVIEW ARTICLEImmune thrombocytopenia: options and new perspectivesCaserta, Santino; Zaccuri, Anna Maria; Innao, Vanessa; Musolino, Caterina; Allegra, Alessandro Author Information Division of Hematology, Department of Human Pathology in Adulthood and Childhood ‘Gaetano Barresi’, University of Messina, Messina, Italy Correspondence to Santino Caserta, Piazza Omero 2, Lazzaro di Motta San Giovanni (RC), 89062, Italy E-mail: [email protected] Received 2 March, 2021 Accepted 25 May, 2021 Blood Coagulation & Fibrinolysis: October 2021 - Volume 32 - Issue 7 - p 427-433 doi: 10.1097/MBC.0000000000001058 Buy Metrics Abstract Immune thrombocytopenia is a haematological, autoimmune disorder characterized by elevated platelet demolition due to the presence of antiplatelet autoantibodies derived from B cells and to an irregular, deficient process of platelets production in bone marrow. In this review, after a brief presentation of ‘old’ strategies used nowadays yet, we focused on new drugs used in the treatment of immune thrombocytopenia and their mechanism of action and posology, basing on the last scientific literature. The observation that CoViD-19 can be associated with immune thrombocytopenia is also put in evidence. Particular attention will be dedicated on the concept that the ideal treatment should represent a solution not only for the failure of normal processes of production and survival of platelets, but also it should improve quality of life of patients, with minimum adverse events. Anyway, despite enormous advances of the last years, further investigations are necessary in order to define scrupulously long-term efficacy of new molecules proposed. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.